本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Arcutis Biotherapeutics Inc.

16.73
+0.85505.39%
成交量:174.84万
成交额:2,838.81万
市值:19.84亿
市盈率:-14.45
高:16.79
开:16.03
低:15.70
收:15.87
数据加载中...

公司资料

公司名字:
Arcutis Biotherapeutics Inc.
交易所:
NASDAQ
成立时间:
2016
员工人数:
342
公司地址:
3027 Townsgate Road,Suite 300,Westlake Village,California,United States
邮编:
91361
电话:
传真:
- -
简介:
Arcutis Biotherapeutics, Inc.前身是根据特拉华州法律于2016年6月成立的,名称为Arcutis,Inc.,后将名称更改为Arcutis Biotherapeutics,Inc.。该公司是一家后期生物制药公司,致力于针对医疗需求未得到满足的皮肤病开发和商业化治疗。他们目前的产品组合包括局部治疗,具有潜在的潜力,可以解决免疫介导的皮肤病和疾病或免疫皮肤病。他们的策略是针对皮肤病学中经过验证的生物学目标识别和开发治疗方法,以提供差异化的临床特征,从而解决现有疗法在目标适应症方面的主要缺点。

董事

名称
职位
Patrick J. Heron
Chairman, Director
Todd Franklin Watanabe
Director, President and Chief Executive Officer
Alexander G. Asam
Director
Bhaskar Chaudhuri
Director
Daniel J. Estes
Director
Jonathan T. Silverstein
Director
Joseph L. Turner
Director
Ricky Sun
Director

股东

名称
职位
Todd Franklin Watanabe
Director, President and Chief Executive Officer
John W. Smither
Chief Financial Officer
Patricia A. Turney
Senior Vice President, Manufacturing
Charlotte Merritt
Vice President, Regulatory Affairs
David Berk
Vice President, Clinical Development
David W. Osborne
Chief Technical Officer
Frank Pompilio
Vice President, Medical Affairs
Howard G. Welgus
Chief Medical Officer
Keith L. Klein
General Counsel
Kenneth A. Lock
Chief Commercial Officer
Lynn Navale
Vice President, Biometrics
Meg Elias
Vice President, Clinical Operations
Scott L. Burrows
Vice President, Finance